Advances in Endocrine Therapy for Breast Cancer

Dear Colleagues,

We invite you to contribute original research, reviews, and expert perspectives to an upcoming Special Issue of our Current Oncology titled “Advances in Endocrine Therapy for Breast Cancer.” This Special Issue will highlight emerging discoveries and innovations shaping the future of hormone-responsive breast cancer care.

Hormone receptor-positive breast cancer, the most common subtype, has a long history of successful treatment using endocrine therapies in both the early and advanced stages of disease. Rapid progress, including novel SERDs, targeted combinations, biomarkers of resistance, and evolving strategies for treatment sequencing, has created an exciting and fast-moving field.

For this Special Issue, we welcome manuscripts focusing on recent advancements in novel endocrine agents, mechanisms, and detection of endocrine resistance, translational and biomarker research, toxicity mitigation and survivorship, disparities in care, and advancements in both metastatic and early disease settings. We also welcome systematic reviews, cost-effectiveness studies, and research into patient-reported outcomes.

We hope you will consider submitting your research and contributing to this Special Issue advancing endocrine therapy research and patient care.

Dr. Sandeep Sehdev
Dr. Arif Ali Awan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.